Irbid Specialty Hospital

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Crohn's disease4 trials
• Ulcerative colitis3 trials
• Duchenne muscular dystrophy1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Spinal cord injury1 trial

Phase

• Phase 34 trials
• Phase 23 trials
• Phase 2/33 trials

Status

• Active, not recruiting6 trials
• Recruiting3 trials
• Completed1 trial

Lead sponsor

• Janssen Research & Development, LLC5 trials
• Boehringer Ingelheim1 trial
• Janssen-Cilag Ltd.1 trial
• Odyssey Therapeutics, Inc.1 trial
• Sarepta Therapeutics, Inc.1 trial
• and 1 more

Running trials

• Recruiting

  Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

  NCT06850727· Phase 2· Odyssey Therapeutics, Inc.· Source

  Contact: Study Coordinator

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

  NCT05491525· Phase 2/3· Urovant Sciences GmbH· Source

  Contact: Osama Bani-Hani (principal investigator)

• Active, not recruiting

  A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease

  NCT05347095· Phase 3· Janssen-Cilag Ltd.· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05242484· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

  NCT05197049· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· Phase 2/3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Spinal cord injury1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

  NCT03992430· Phase 3· Sarepta Therapeutics, Inc.· Source